Polycythaemia vera – Diagnostics – Overview of Information and Clinical Research

Discovering that your body is producing too many red blood cells can feel overwhelming, but understanding how polycythemia vera is diagnosed is the first step toward managing this rare blood condition effectively.

Introduction: When to Seek Diagnostic Testing

Many people with polycythemia vera have no idea they have the condition until a routine blood test reveals something unexpected. This is because the disease develops very slowly, often over many years, and early symptoms can be so subtle that they’re easily overlooked or attributed to other causes. The condition is most commonly discovered during regular health check-ups when blood tests are ordered for completely unrelated reasons.^[1]

If you’re experiencing certain symptoms, it’s important to schedule an appointment with your healthcare professional. Warning signs that should prompt you to seek medical attention include persistent headaches, dizziness, unexplained tiredness that doesn’t improve with rest, or blurred vision. Some people notice intense itching, especially after taking a warm bath or shower, which is a distinctive feature of this condition. You might also experience a feeling of fullness soon after eating, or notice unusual bleeding such as frequent nosebleeds or bleeding gums.^[1]^[2]

Another important sign is a reddish or flushed appearance of the skin, particularly on the face, which can look like a persistent sunburn. Some individuals develop painful swelling in their joints, often affecting the big toe, or feel numbness, tingling, or burning sensations in their hands and feet. If you notice shortness of breath, especially when lying down, or experience bone pain, these symptoms warrant medical evaluation.^[1]^[6]

It’s worth noting that polycythemia vera affects people differently. While many individuals show no symptoms at all during the early stages, others may develop noticeable problems that interfere with daily life. The condition is more common in people over the age of 60, though it can occur at any age. Men are slightly more likely to develop it than women.^[3]^[4]

⚠️ Important

Don’t wait to seek medical attention if you develop symptoms that concern you. The most serious risk from polycythemia vera is the formation of blood clots, which can lead to heart attack or stroke. Early diagnosis allows your healthcare team to begin treatment that reduces this risk and helps prevent serious complications.

Classic Diagnostic Methods

When your doctor suspects polycythemia vera, the diagnostic process typically begins with a thorough medical history and physical examination. During the exam, your healthcare professional will look for physical signs of the condition, such as redness of the skin or an enlarged spleen on the left side of your abdomen. The spleen is an organ that filters blood, and in people with this condition, it often becomes swollen because it’s working overtime to process the excess blood cells.^[9]

Blood Tests

The cornerstone of diagnosing polycythemia vera is blood testing. A complete blood count (which doctors often call a CBC) measures the numbers of different types of cells in your blood. This test will reveal whether you have more red blood cells than normal. In many cases, it also shows elevated white blood cells and platelets, though the red blood cell increase is the most prominent feature.^[4]^[9]

The blood test also measures your hematocrit, which is the percentage of your blood volume that consists of red blood cells, and your hemoglobin level, which is the iron-rich protein in red blood cells that carries oxygen throughout your body. In healthy adult men, normal hemoglobin is around 16 grams per deciliter, give or take 2, with hematocrit around 47%, plus or minus 6%. For women who menstruate, typical hemoglobin is about 13 grams per deciliter, give or take 2, with hematocrit around 40%, plus or minus 6%. In polycythemia vera, these numbers are significantly higher.^[9]^[13]

Another crucial blood test measures erythropoietin, which is a hormone your body produces to signal your bone marrow to make red blood cells. In polycythemia vera, this hormone level is typically low. This finding helps distinguish polycythemia vera from other conditions that cause too many red blood cells. When the body genuinely needs more oxygen-carrying capacity (such as at high altitudes or with lung disease), erythropoietin levels are high. But in polycythemia vera, the red blood cells are being produced without the normal signals, so erythropoietin levels drop.^[4]^[5]

Gene Mutation Testing

One of the most important diagnostic tests looks for a specific genetic change in your blood cells. Approximately 95% to 98% of people with polycythemia vera have a mutation called JAK2V617F in the gene that controls blood cell production. This mutation causes cells to grow and multiply without the normal controls that keep blood cell numbers balanced. The test for this mutation is done on a blood sample and provides strong evidence for the diagnosis.^[3]^[5]^[7]

In the small percentage of patients who don’t have the JAK2V617F mutation, doctors may find other changes in the JAK2 gene, such as mutations in exon 12, or occasionally mutations in other genes like TET2. These genetic tests are critical because they help confirm that the increased red blood cells are due to polycythemia vera and not another cause.^[3]^[7]

Bone Marrow Examination

If your doctor needs more information to confirm the diagnosis, they may recommend a bone marrow biopsy or bone marrow aspiration. These procedures involve taking a small sample of your bone marrow, usually from the back of your hip bone. During an aspiration, a thin needle is used to withdraw a small amount of the liquid portion of the marrow. A biopsy removes a tiny piece of the solid bone tissue along with the marrow inside it. These procedures are often done together at the same time.^[9]

Examining your bone marrow under a microscope allows doctors to see an excess of cells that develop into red blood cells, along with increased numbers of white blood cell and platelet precursors. This cellular picture helps distinguish polycythemia vera from other blood conditions. In some cases, the bone marrow examination may also reveal abnormalities in the chromosomes of blood-forming cells, which are present in about 20% of people at the time of diagnosis.^[3]^[4]

Additional Laboratory Tests

Your doctor may order several other blood tests to get a complete picture of your health. These might include a comprehensive metabolic panel to check your kidney and liver function, tests to measure uric acid levels (which are often high in polycythemia vera and can lead to gout or kidney stones), and vitamin B12 levels (which may be elevated). An oxygen saturation test helps rule out low oxygen levels as a cause of increased red blood cells.^[4]

Other specialized tests that may be performed include measuring the activity of an enzyme called leukocyte alkaline phosphatase in white blood cells, checking your erythrocyte sedimentation rate (a marker of inflammation), and measuring lactate dehydrogenase (an enzyme that can indicate how quickly cells are being produced and broken down).^[4]

Distinguishing From Other Conditions

An important part of diagnosis is ruling out other causes of increased red blood cells. Some conditions that can cause similar blood test results include chronic lung diseases, heart conditions, kidney tumors, or simply living at high altitude where the body naturally produces more red blood cells to compensate for lower oxygen levels. This is why measuring erythropoietin levels and testing for the JAK2 mutation are so valuable—they help doctors distinguish polycythemia vera from these other causes.^[4]^[13]

Sometimes people have what’s called spurious polycythemia, where blood tests suggest too many red blood cells, but the real problem is actually a loss of blood plasma volume due to dehydration or other causes. This makes the blood appear more concentrated than it truly is. Careful evaluation helps distinguish this from true polycythemia vera.^[13]

Diagnostics for Clinical Trial Qualification

When researchers design clinical trials to test new treatments for polycythemia vera, they establish specific diagnostic criteria that participants must meet. These criteria ensure that everyone enrolled in the study truly has the condition and that researchers can accurately measure whether the experimental treatment is working.

For clinical trials, diagnosis typically requires meeting specific blood count thresholds. Most trials require documented evidence of elevated hemoglobin and hematocrit levels that meet established cutoffs for polycythemia vera. The exact numbers may vary slightly between studies, but they generally align with recognized diagnostic criteria. Participants must also have confirmed presence of the JAK2 mutation or other characteristic genetic changes.^[3]^[5]

Many clinical trials also require that participants have a history of needing frequent phlebotomies—a procedure where blood is removed from the body to reduce the number of red blood cells. For example, recent studies have enrolled people who needed a certain number of phlebotomies per year before joining the trial, as this indicates their disease was active and not fully controlled by their current treatment.^[14]

Researchers conducting clinical trials carefully track several measurements throughout the study. They monitor hematocrit levels regularly to see if they remain below 45%, which is the target for good disease control. They count how many phlebotomies each participant needs during the trial period. They also may assess spleen size using physical examination or imaging tests like ultrasound, since many people with polycythemia vera develop an enlarged spleen. Some trials track symptoms using standardized questionnaires to measure how treatment affects quality of life.^[14]

Before enrolling in a clinical trial, participants undergo comprehensive baseline testing to establish their starting point. This typically includes complete blood counts, genetic testing to confirm the JAK2 mutation or other relevant mutations, measurement of erythropoietin levels, and assessment of other blood parameters. Bone marrow examination may be required in some trials, particularly those testing treatments that might affect how the bone marrow produces blood cells.^[3]

Clinical trials may exclude people whose polycythemia vera has transformed into more aggressive conditions like acute myeloid leukemia or severe myelofibrosis (when bone marrow becomes scarred and can no longer produce blood cells normally). These complications represent advanced disease that requires different treatment approaches.^[2]^[4]

⚠️ Important

If you’re interested in participating in a clinical trial, your healthcare team can help determine whether you meet the specific eligibility criteria. Clinical trials often provide access to new treatments before they become widely available, and they contribute valuable information that helps improve care for future patients with polycythemia vera.

Throughout a clinical trial, participants continue to receive regular diagnostic monitoring to track their disease status and detect any changes. This ongoing testing helps researchers understand how well the experimental treatment is working and identify any potential side effects early. The frequency and type of testing are specified in the trial protocol and are typically more intensive than routine clinical care.^[14]

Prognosis and Survival Rate

Prognosis

The outlook for people with polycythemia vera has improved significantly with modern medical care, and most people with this condition can live for many years while managing their symptoms. The disease progresses very slowly, which means that with proper monitoring and treatment, many individuals maintain good quality of life for extended periods. The condition itself is chronic, meaning it doesn’t go away, but it can be controlled.^[2]^[5]

The most important factor affecting prognosis is the risk of blood clots, which is the primary danger posed by the thickened blood. With appropriate treatment to keep red blood cell counts in a healthy range, this risk can be substantially reduced. People who develop complications such as blood clots in major vessels, progression to more severe bone marrow conditions, or transformation to acute leukemia may face more serious health challenges. However, these severe outcomes are relatively uncommon with good medical management.^[2]^[4]

Several factors can influence an individual’s prognosis. Age at diagnosis plays a role, with people diagnosed after age 60 having different considerations than younger patients. A history of blood clots before diagnosis suggests higher risk. The presence of certain genetic abnormalities beyond the JAK2 mutation may indicate more aggressive disease. How well the condition responds to initial treatment also provides information about likely outcomes.^[3]

Over time, approximately 15% of people with polycythemia vera may develop progression to other conditions. The bone marrow can become scarred in a process called myelofibrosis, which makes it harder for the marrow to produce healthy blood cells. In rare cases—less than 5% of patients—the disease may transform into acute myeloid leukemia, a more aggressive type of blood cancer. These transformations are more likely to occur many years after diagnosis, particularly in people who have had the disease for more than a decade.^[2]^[4]^[5]

Survival rate

Most people with polycythemia vera enjoy good longevity when they receive regular medical monitoring and appropriate treatment. The disease itself is not immediately life-threatening, and many individuals live for decades after diagnosis. Studies have shown that people with well-controlled polycythemia vera can have survival rates that approach those of the general population, particularly when treatment successfully prevents blood clots and other complications.^[4]^[5]

The median age at diagnosis is around 60 years, and with modern treatment approaches, many people diagnosed at this age can expect to live many more years. Younger patients diagnosed in their 40s or 50s often have survival measured in decades. The key to these positive outcomes is consistent medical care that keeps blood counts in the target range and prevents the serious complications that can threaten health and life.^[3]^[4]

Survival can be challenged when complications develop. The risk of life-threatening blood clots—particularly those causing heart attack, stroke, or pulmonary embolism—represents the most immediate threat to survival. Other factors that can affect longevity include progression to myelofibrosis or leukemia, development of secondary conditions like severe infections, or complications from excess uric acid such as kidney damage. However, with careful medical management, many of these complications can be prevented or their impact minimized.^[2]^[4]

#1 Clinical Trials Search in Europe